The NHS has long been accused of lagging behind other European nations in embracing cutting-edge treatments. However, a significant shift in how the National Institute for Health and Care Excellence (NICE) evaluates the value of new medicines may be helping to change that.
Over the past three months, several innovative treatments have reached NHS patients who might otherwise have been denied access due to concerns over cost. These include groundbreaking therapies for various cancers, specific blood disorders, and a range of autoimmune conditions. According to Richard Torbett of the Association of the British Pharmaceutical Industry (ABPI), this progress is largely down to an increase in NICE's threshold for evaluating the value of new treatments.
For nearly a quarter of a century, NICE's cost-effectiveness threshold remained unchanged, making it challenging for some innovative medicines to gain approval. The updated approach aims to better reflect the rapidly evolving landscape of pharmaceutical innovation and the long-term benefits these treatments can offer patients. By doing so, the NHS is now more likely to approve treatments that may not have been deemed 'cost-effective' under the previous regime.
However, this shift in policy has not gone unchallenged. Some experts had previously warned that a US-UK pharmaceutical agreement could lead to a substantial number of excess deaths in England due to increased NHS spending on expensive medicines. Industry representatives have dismissed these claims as 'alarmist', arguing that they rely on incomplete data and modelling approaches.
The discussions highlight the ongoing tension between ensuring access to the latest medical advancements and managing the financial pressures on the NHS. While some have criticised the reforms as a public health threat, industry voices argue that they represent a positive step towards aligning the UK's approach with international standards for valuing and adopting new pharmaceutical innovations.
The ABPI maintains that these reforms will ultimately lead to better patient outcomes and increased investment in future medicines. As Nick Hoile of MHP Group notes, 'this modest, long-overdue adjustment' to how the NHS values innovation is a necessary step towards ensuring that patients have access to life-changing treatments.